NFL Biosciences SA

Paris Stock Exchange ALNFL.PA

NFL Biosciences SA Return on Equity (ROE) for the year ending December 31, 2023: -1,070.30%

NFL Biosciences SA Return on Equity (ROE) is -1,070.30% for the year ending December 31, 2023. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • NFL Biosciences SA Return on Equity (ROE) for the year ending December 31, 2021 was -29.76%.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
SV Wall Street
Paris Stock Exchange: ALNFL.PA

NFL Biosciences SA

CEO Dr. Ignacio Faus M.B.A., Ph.D.
IPO Date July 5, 2021
Location France
Headquarters 199 Rue Helene Boucher
Employees 4
Sector Health Care
Industries
Biotechnology Pharmaceuticals Tobacco
Description

NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

Similar companies

ABNX.PA

ABIONYX Pharma SA

USD 1.28

-1.09%

StockViz Staff

January 31, 2025

Any question? Send us an email